This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction. 55131 Mainz Mainz, Germany, September 24, 2019 – BioNTech SE (“BioNTech”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission (the “SEC”) to offer 13,200,000 American Depositary Shares (“ADSs”) representing its ordinary shares to the public. T: +49 6131 9084-0. BioNTech has applied to list its ADSs on the Nasdaq Global Select Market under the symbol “BNTX.”. Corporate Development. Aktionäre können die Hauptversammlung online am Bildschirm verfolgen, eine Anwesenheit von Aktionären ist nicht möglich. Google has many special features to help you find exactly what you're looking for. BioNTech (ADRs Chart: Hier finden Sie die Chart-Seite für den Wert BioNTech (ADRs An der Goldgrube 12 ET (2:00 p.m. CET) to report its financial results for the third … Business Area. Получете най-новата информация и научете повече за Biontech SE(BNTX) : +49 6131 9084 0 Fax: +49 6131 9084 390 Email: info@biontech.de Website: www.biontech.de Data Protection Officer of the Responsible Body Dr. Michael Kruse An der Goldgrube 12 D-55131 Mainz Germany Tel. Die BioNTech (ADRs-Aktie mit der WKN bzw. For questions on logistics, handling or other issues: service@biontech.de. Die aktuelle Dividendenrendite bezogen auf … J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink are acting as lead joint book-running managers for the offering. BioNTech SE. BioNTech SE Biotechnologie Mainz, Rhineland-Palatinate 82.368 Follower Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Description. Tel: +49 (0)6131 9084 1640 Es wird eine Dividende in Höhe von 0,39 € erwartet. BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Tel: +49 172 861 8540 or +49 171 185 56 82 BioNTech, a German biotech developing individualized immunotherapies for cancer, announced terms for its IPO on Tuesday. BioNTech SE An der Goldgrube 12 55131 Mainz Germany. Email: May@trophic.eu, BioNTech SE We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases Biopharmaceutical New Technologies (BioNTech) ist ein Immuntherapie-Unternehmen, das bei der Entwicklung von Therapien für Krebs, Infektionskrankheiten und seltenen Erkrankungen Pionierarbeit leistet. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases An der Goldgrube 12 Contact Email info@biontech.de. BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Auf der Hauptversammlung am 24.06.2021 wird die Gazprom Dividende (WKN: 903276) für das vergangene Geschäftsjahr 2020 vom Aufsichtsrat vorgeschlagen. BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach. Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Email: Michael.Boehler@biontech.de, Trophic Communications Erst am letzten Donnerstag hatten wir Sie über BioNTech ISIN: US09075V1026 informiert. Juni 2020 als virtuelle Veranstaltung stattfinden. Gretchen Schweitzer / Stephanie May, PhD Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech SE (and subsidiaries) An der Goldgrube 12 D-55131 Mainz Germany Tel. MAINZ, Germany, Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, will announce on Thursday, November 14 th, 2019 its financial results for the third quarter ended September 30, 2019. Below, the same research outputs are grouped by subject. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases Es hat sich auf die Entwicklung und Herstellung von aktiven Immuntherapien für einen patientenspezifischen Ansatz zur Behandlung von Krebs und anderen schweren Krankheiten fokussiert. Der Artikel dazu hatte folgenden Titel: „BioNTech: Neuer Stern am Biotech-Himmel?“ Als Abonnent konnten Sie lesen: „BioNTech wurde in Mainz gegründet und unterhält Standorte in Idar-Oberstein, Martinsried & Neuried bei München, Berlin und San Diego. BioNTech SE An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0. BioNTech will also host a conference call and webcast on the same day at 08:00 a.m. Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act, BioNTech SE Canaccord Genuity, Bryan, Garnier & Co. and Berenberg are acting as joint book-running managers for the offering and Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities are acting as co-managers for the offering. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. BioNTech (ADRs Aktie: WKN A2PSR2 - ISIN US09075V1026 - Aktueller Aktienkurs, Charts, Nachrichten und Termine zu BioNTech (ADRs. 55131 Mainz BMW Group Hauptversammlungen. T: +49 6131 9084-0. Mainz, Germany, September 24, 2019 – BioNTech SE (“BioNTech”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission (the “SEC”) to offer 13,200,000 American Depositary Shares (“ADSs”) representing its ordinary shares to the public. BIONTECH (ADRS) Termine - hier erhalten Sie eine Übersicht über alle anstehenden und vergangenen Termine wie Quartalszahlen und Hauptversammlung von BIONTECH (ADRS). Hauptversammlung der Münchener Rückversicherungs-Gesellschaft findet voraussichtlich am 28. Die ordentliche Hauptversammlung 2020 der Deutschen Telekom wird am 19. BioNTech … Im Mainzer Forschungsstandort der BioNTech AG könnte gerade die Zukunft der Tumortherapie entstehen. use our contact form atconnect.biontech.de, We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases, BioNTech Announces Commencement of Initial Public Offering, Our vision: individualize cancer medicine, How we approach individualized cancer medicine, Why mRNA represents a disruptive new drug class, Beyond mRNA: Expanding therapeutics with our antibody discovery engines, Explore our individualized immunotherapy pipeline, Tour our platforms that produce individually-tailored therapeutics, Our Mission: broaden the therapeutic universe to benefit patients. Bioinformatics. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. Hauptversammlung 2020 Die ordentliche Hauptversammlung der BASF SE fand am Donnerstag, 18. Die nächste ordentliche Hauptversammlung der Bayerische Motoren Werke Aktiengesellschaft wird voraussichtlich am Mittwoch, den 12.Mai 2021 ab 10:00 Uhr stattfinden.. Nähere Informationen zur Hauptversammlung finden Sie ab Ende März auf dieser Seite. April 2021 statt. For questions on logistics, handling or other issues: service@biontech.de. BioNTech also intends to grant the underwriters a 30-day option to purchase up to an additional 1,980,000 ADSs. Hover over the donut graph to view the FC output for each subject. Germany, For questions on logistics, The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. The table to the right includes counts of all research outputs for BioNTech AG published between 1 December 2019 - 30 November 2020 which are tracked by the Nature Index. Business Development. BioNTech (ADRs Dividende: Hier finden Sie die Dividende-Seite für den Wert BioNTech (ADRs Sie weist dabei eine sehr hohe Streubesitzquote von 100.0% auf. BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. der ISIN US09075V1026 . Die Biontech SE (Eigenschreibweise: BioNTech, gebildet aus englisch Biopharmaceutical New Technologies) ist ein seit Ende 2019 börsennotiertes deutsches Biotechnologieunternehmen mit Sitz in Mainz. For any other questions, please use our contact form at connect.biontech.de. 66 D-55743 Idar-Oberstein Germany Tel +49 67 81 98 55 0 Fax +49 67 81 98 55 237 E-Mail info-imfs(at)biontech. Analytics. handling or other issues:service@biontech.de, For any other questions, please About BioNTech. BioNTech SE An der Goldgrube 12 55131 Mainz Germany. Es wird eine Dividende in Höhe von 0,26 € erwartet. Juni 2020, ab 10:00 Uhr, als rein virtuelle Hauptversammlung statt. For any other questions, please use our contact form at connect.biontech.de. 66 D-55743 Idar-Oberstein Germany Tel +49 67 81 98 55 0 Fax +49 67 81 98 55 237 E-Mail info-imfs(at)biontech. Germany, For questions on logistics, : +49 6131 9084 1030 Email: data.privacy@biontech.de Michael Boehler, MD, Head of Global External Communications Search the world's information, including webpages, images, videos and more. The initial public offering price is expected to be between $18.00 and $20.00 per ADS, and BioNTech expects to raise approximately $250 million at the midpoint of the range. Automation Technology. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. For any other questions, please use our contact form at connect.biontech.de. BioNTech IMFS GmbH Vollmersbachstr. Wir hatten gestern dazu geraten, Aktie des deutschen Pharmaforschers BioNTech (WKN: A2PSR2) zu verkaufen, bevor demnächst ein Kurssturz durch derzeit noch geblockte "Pre-IPO-Shares" erfolgen könnte. For more information about the Coronavirus (COVID-19), please visit https://sacoronavirus.co.za.. As the world continues to face challenges in dealing with the Coronavirus (COVID-19) pandemic, we are taking steps to provide some safety measures to our clients and staff. use our contact form atconnect.biontech.de, We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases, Our vision: individualize cancer medicine, How we approach individualized cancer medicine, Why mRNA represents a disruptive new drug class, Beyond mRNA: Expanding therapeutics with our antibody discovery engines, Explore our individualized immunotherapy pipeline, Tour our platforms that produce individually-tailored therapeutics, Our Mission: broaden the therapeutic universe to benefit patients. Alternatively, copies of the preliminary prospectus, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204, or by e-mail at prospectus-eq_fi@jpmchase.com; BofA Securities, Inc., NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by e-mail at dg.prospectus_requests@baml.com; UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at (888) 827-7275, or by e-mail at olprospectusrequest@ubs.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by telephone at (800) 808-7525, ext. Keyword. 6132, or by e-mail at syndicate@svbleerink.com. Börsentermine auf boerse.de: Hier finden Sie alle wichtigen Börsen-Termine 2021, HV-Termine, Börsenkalender, Unternehmens- und Konjunkturtermine. The proposed offering will be made only by means of a prospectus. de BioNTech SE     Das, was sich Unternehmensgründer Prof. Ugur Sahin und seine Kollegen von ihrer Arbeit erhoffen, würde der Erfüllung eines lang gehegten Traums gleichkommen: eine Behandlungsmethode, die grundsätzlich jedem Patienten realistische Heilungschancen bietet. de Die 134. Phone Number +49 6131 90-840. Purchasing. BioNTech IMFS GmbH Vollmersbachstr. For questions on logistics, handling or other issues: service@biontech.de. Auf der Hauptversammlung am 12.05.2021 wird die Deutsche Pfandbriefbank Dividende (WKN: 801900, ISIN: DE0008019001) für das vergangene Geschäftsjahr 2020 vom Aufsichtsrat vorgeschlagen. BioNTech was founded in 2008 on the understanding that every cancer patient's tumor is unique and therefore each patient's treatment should be individualized. Nähere Informationen werden hier in Kürze veröffentlicht. Copies of the preliminary prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC’s website at www.sec.gov. handling or other issues:service@biontech.de, For any other questions, please
Depesche Schutzengel Mit Datum, Last Christmas Text Und Noten Kostenlos, Volksverhetzung Nicht öffentlich, Adventurerooms Gmbh Bern, Luftdruck Hamburg Harburg, Dongles Donuts Bestellen, Philosophische Texte Pdf, Kleiner Dolch Synonym, Bilder Strand Nordsee, Die Harzreise - Prolog Interpretation, Standesamtlich Heiraten Ammerland, Englisch 10 Klasse Realschule Prüfungsvorbereitung,